AASLD 2025 The Liver Meeting®

AASLD 2025 The Liver Meeting®
November 07-11, 2025
Washington D.C.

American Association for the Study of Liver Diseases, The Liver Meeting® .

Explore more information for Gilead Liver Diseases therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (22)

    INTEGRATED VIROLOGY ANALYSIS OF BULEVIRTIDE (BLV) MONOTHERAPY IN CHRONIC HEPATITIS DELTA: POOLED DATA FROM MYR301 AND MYR204

    • Author(s): Richards, C
    • hepcludex
    • Liver Diseases

    A Higher Proportion of Unglycosylated HBsAg is Predictive of Faster HBsAg Decline Kinetics In Patients with Chronic Hepatitis B

    • Author(s): Li, Chunfeng
    • vemlidy
    • Liver Diseases

    REAL-WORLD PERSISTENCY OF BULEVIRTIDE THERAPY IN CHRONIC HEPATITIS D PATIENTS IN GERMANY: A RETROSPECTIVE OBSERVATIONAL ANALYSIS

    • Author(s): Nierhoff, D
    • hepcludex
    • Liver Diseases

    36 MONTHS OF TREATMENT WITH SELADELPAR IS ASSOCIATED WITH STABLE OR IMPROVED LIVER STIFFNESS IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS

    • Author(s): Bowlus, C
    • livdelzi
    • Liver Diseases

    PATIENT-REPORTED BURDEN AND HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITH HEPATITIS DELTA: RESULTS FROM A REAL-WORLD STUDY IN EUROPE

    • Author(s): Lampertico, P
    • hepcludex
    • Liver Diseases

    IMPROVEMENTS IN PATIENT-REPORTED GENERAL HEALTH AND WELL-BEING IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS TREATED WITH SELADELPAR IN THE RESPONSE TRIAL

    • Author(s): Kumar, S
    • livdelzi
    • Liver Diseases

    EFFICACY AND SAFETY OF SELADELPAR VS. ELAFIBRANOR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS: A MATCHING-ADJUSTED INDIRECT COMPARISON

    • Author(s): Jones, D
    • livdelzi
    • Liver Diseases

    PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF BULEVIRTIDE 10 MG ONCE DAILY FOR 6 DAYS IN PARTICIPANTS WITH SEVERE HEPATIC IMPAIRMENT AND IN MATCHED CONTROL PARTICIPANTS WITH NORMAL HEPATIC FUNCTION

    • Author(s): Kumar, P
    • hepcludex
    • Liver Diseases

    REAL-WORLD EXPERIENCE OF SELADELPAR AMONG PATIENTS WITH PRIMARY BILIARY CHOLANGITIS INCLUDING PATIENTS SWITCHED FROM OBETICHOLIC ACID

    • Author(s): Bowlus, C
    • livdelzi
    • Liver Diseases

    REDUCTION IN ITCH-ASSOCIATED DISABILITY AND PRURITUS DISTRIBUTION IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS TREATED WITH SELADELPAR IN THE RESPONSE TRIAL

    • Author(s): Kremer, A
    • livdelzi
    • Liver Diseases

    EFFICACY AND SAFETY OF SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS AND ELEVATED BILIRUBIN AT BASELINE IN THE PHASE 3 PLACEBO-CONTROLLED RESPONSE TRIAL

    • Author(s): Kumar, S
    • livdelzi
    • Liver Diseases

    SELADELPAR LEADS TO SUSTAINED, CLINICALLY MEANINGFUL IMPROVEMENT IN PRURITUS: RESULTS FROM THE ASSURE STUDY UP TO 30 MONTHS

    • Author(s): Hirschfield, G
    • livdelzi
    • Liver Diseases

    PERSISTENT LOW VIREMIC RELAPSE VS HIGH VIREMIC RELAPSE AFTER THE END OF TREATMENT WITH BULEVIRTIDE WITH OR WITHOUT PEGYLATED INTERFERON IN PATIENTS WITH CHRONIC HEPATITIS DELTA VIRUS

    • Author(s): Zoulim, F
    • hepcludex
    • Liver Diseases

    SELADELPAR LEADS TO SUSTAINED REDUCTION IN CHOLESTATIC MARKERS WITH CONSISTENT SAFETY PROFILE IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS TREATED UP TO 48 MONTHS

    • Author(s): Pratt, D
    • livdelzi
    • Liver Diseases

    ELEVATIONS IN TOTAL SERUM BILE ACIDS DURING BULEVIRTIDE TREATMENT ARE ASYMPTOMATIC AND NOT ASSOCIATED WITH ADVERSE EVENTS OF INTEREST IN PATIENTS WITH CHRONIC HEPATITIS DELTA

    • Author(s): Lampertico, P
    • hepcludex
    • Liver Diseases

    REAL-WORLD IMPLICATIONS OF THE NEW AASLD/IDSA HCV "TEST AND TREAT" ALGORITHM: FOCUS ON CARDIOVASCULAR COMEDICATIONS IN HEPATITIS C VIRUS (HCV) PATIENTS RECEIVING DIRECT-ACTING ANTIVIRALS (DAAS)

    • Author(s): Makhija, D
    • epclusa
    • Liver Diseases

    SUSTAINED EFFICACY AND SAFETY OF SELADELPAR FOR UP TO 36 MONTHS IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS FROM THE PLACEBO-CONTROLLED RESPONSE STUDY TO THE OPEN-LABEL ASSURE STUDY

    • Author(s): Levy, C
    • livdelzi
    • Liver Diseases

    A RANDOMIZED, PLACEBOCONTROLLED, PHASE 2 STUDY OF THE SAFETY AND EFFICACY OF COMBINATION TREATMENT WITH SEMAGLUTIDE, CILOFEXOR AND FIRSOCOSTAT IN PATIENTS WITH COMPENSATED CIRRHOSIS DUE TO METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (WAYFIND)

    • Author(s): Alkhouri, N
    • cilofexor/firsocostat/semaglutide
    • Liver Diseases

    SAFETY, TOLERABILITY, IMMUNOGENICITY, AND ANTIVIRAL EFFICACY OF GS-2829 AND GS-6779, A NOVEL, ARENAVIRAL-VECTORED, THERAPEUTIC HEPATITIS B VACCINE: RESULTS FROM A PHASE 1B STUDY IN VIRALLY SUPPRESSED PATIENTS WITH CHRONIC HEPATITIS B

    • Author(s): Gane, E
    • gs-2829
    • Liver Diseases

    EXPOSURE TO TENOFOVIR ALAFENAMIDE AND TENOFOVIR DISOPROXIL FUMARATE AND THE RISK OF HEPATOCELLULAR CARCINOMA

    • Author(s): Ray Kim, W
    • vemlidy
    • Liver Diseases

    CUMULATIVE REVIEW OF SOFOSBUVIR/VELPATASVIR EXPOSURE IN PREGNANT WOMEN WITH HEPATITIS C FROM A PHARMACOVIGILANCE SAFETY DATABASE

    • Author(s): Chappell, C
    • epclusa
    • Liver Diseases

    IS SVR4 TESTING AN ACCEPTABLE ALTERNATIVE MEASURE OF HCV CURE IN RE-TREATED PATIENTS FOLLOWING DAA FAILURE? A SVR 4/12 CONCORDANCE EVALUATION FROM THE POLARIS CLINICAL TRIALS

    • Author(s): Scherbakovsky, S
    • vosevi
    • Liver Diseases